Minerva Neurosciences, Inc (NERV) Set to Announce Quarterly Earnings on Wednesday
Minerva Neurosciences, Inc (NASDAQ:NERV) is scheduled to be issuing its quarterly earnings data after the market closes on Wednesday, November 1st.
Minerva Neurosciences (NASDAQ:NERV) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.07. During the same quarter in the previous year, the company earned ($0.18) EPS. On average, analysts expect Minerva Neurosciences to post $-1.26 EPS for the current fiscal year and $-1.54 EPS for the next fiscal year.
Minerva Neurosciences, Inc (NASDAQ:NERV) opened at 6.90 on Wednesday. Minerva Neurosciences, Inc has a 52 week low of $5.55 and a 52 week high of $14.15. The firm’s 50-day moving average is $7.28 and its 200-day moving average is $7.61. The stock’s market capitalization is $293.31 million.
COPYRIGHT VIOLATION NOTICE: “Minerva Neurosciences, Inc (NERV) Set to Announce Quarterly Earnings on Wednesday” was originally published by American Banking News and is owned by of American Banking News. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/10/25/minerva-neurosciences-inc-nerv-set-to-announce-quarterly-earnings-on-wednesday.html.
NERV has been the topic of several analyst reports. Zacks Investment Research raised shares of Minerva Neurosciences from a “hold” rating to a “buy” rating and set a $6.75 price target on the stock in a research note on Tuesday, August 22nd. Citigroup Inc. initiated coverage on shares of Minerva Neurosciences in a research note on Friday, September 1st. They set a “buy” rating and a $11.00 price target on the stock. Finally, BidaskClub cut shares of Minerva Neurosciences from a “hold” rating to a “sell” rating in a research note on Monday, July 24th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $13.94.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.
Receive News & Ratings for Minerva Neurosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.